At TechCrunch Disrupt 2026, a leading biotech entrepreneur will explore the intersection of AI, synthetic biology, and conservation, challenging the limits of what technology can achieve in restoring lost species and ecosystems.
- Colossal Biosciences uses AI and synthetic biology to pursue de-extinction.
- TechCrunch Disrupt hosts keynote fireside chat with CEO Ben Lamm.
- Discussion tackles ethical and ecological implications of engineered nature.
What happened
TechCrunch Disrupt 2026 features a high-profile conversation with Ben Lamm, CEO of Colossal Biosciences, a company pioneering the use of AI and synthetic biology to bring extinct species back to life. This session, titled “Can We Engineer Nature’s Comeback?”, will delve into how cutting-edge technologies are shifting the boundaries of conservation research and biodiversity restoration.
Lamm’s company is at the forefront of applying AI to analyze genetic data and accelerate biological discovery, transforming ideas that were once considered science fiction into actionable scientific endeavors. The event attracts thousands of founders, investors, and operators eager to explore how AI is disrupting life sciences alongside software and robotics.
Why it matters
The integration of AI with synthetic biology marks a potential turning point in how humanity addresses biodiversity loss and ecosystem resilience. With Colossal Biosciences leading efforts in de-extinction, deeper ethical and ecological questions arise concerning whether reviving extinct species represents a breakthrough in conservation or a diversion from protecting existing natural habitats.
These discussions highlight the broader implications of using AI beyond digital domains into biological systems and climate science, challenging stakeholders to consider the responsibilities and risks inherent in re-engineering living organisms at scale. The debate will shape future policies and investment in emerging biotechnologies.
What to watch next
The ongoing conversation at TechCrunch Disrupt signals increasing interest and scrutiny on the intersection of AI, synthetic biology, and environmental science. Observers should monitor how regulatory frameworks evolve to govern such technologies and how public opinion shapes funding priorities and scientific research agendas.
For startups and investors in deep tech and life sciences, tracking Colossal’s progress and the outcomes of these debates will be critical as they represent the forefront of applying AI to one of humanity’s greatest challenges: restoring and preserving biodiversity in a changing world.